Tetsuhiko Asao

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

Postoperative recurrence defines a 3-year high-risk window in patients with EGFR-mutant lung adenocarcinoma: a multicenter cohort study.

Postoperative recurrence defines a 3-year high-risk window in patients with EGFR-mutant lung adenocarcinoma: a multicenter cohort study.

Journal: Journal of thoracic disease
Published: April 20, 2026

Development of a multimodal fully automated ensemble model to predict EGFR mutation and efficacy of EGFR-TKI in non-small cell lung cancer.

Development of a multimodal fully automated ensemble model to predict EGFR mutation and efficacy of EGFR-TKI in non-small cell lung cancer.

Journal: Translational lung cancer research
Published: June 08, 2025

Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial.

Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial.

Journal: The Lancet. Respiratory medicine
Published: April 08, 2025

Epidemiology and clinical course of large cell neuroendocrine carcinoma of the lung: The Japanese lung cancer registry study.

Epidemiology and clinical course of large cell neuroendocrine carcinoma of the lung: The Japanese lung cancer registry study.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 02, 2025

Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial.

Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Oncology
Published: October 01, 2024

Adjuvant Chemotherapy Decisions in the Treatment of Lung Cancer Considering Nonrelapse Mortality: A Multicenter Study.

Adjuvant Chemotherapy Decisions in the Treatment of Lung Cancer Considering Nonrelapse Mortality: A Multicenter Study.

Journal: Clinical lung cancer
Published: September 18, 2024

Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity.

Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity.

Journal: Cancer cell
Published: July 24, 2024

Tumour-derived Extracellular Vesicle and Particle Reprogramming of Interstitial Macrophages in the Lung Pre-Metastatic Niche Enhances Vascular Permeability and Metastatic Potential.

Tumour-derived Extracellular Vesicle and Particle Reprogramming of Interstitial Macrophages in the Lung Pre-Metastatic Niche Enhances Vascular Permeability and Metastatic Potential.

Journal: Research square
Published: June 10, 2024

Second malignancy in advanced or recurrent non-small cell lung cancer after the advent of molecular targeted drugs and immunotherapy.

Second malignancy in advanced or recurrent non-small cell lung cancer after the advent of molecular targeted drugs and immunotherapy.

Journal: Thoracic cancer
Published: June 03, 2024

Extracellular vesicles and particles as mediators of long-range communication in cancer: connecting biological function to clinical applications.

Extracellular vesicles and particles as mediators of long-range communication in cancer: connecting biological function to clinical applications.

Journal: Extracellular vesicles and circulating nucleic acids
Published: May 06, 2024

Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).

Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).

Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 30, 2024

Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.

Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.

Journal: JAMA oncology
Published: March 07, 2024
Showing 1-12 of 54

Last Updated: 09/26/2026